Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
IPP-204106 by Immupharma for Pancreatic Cancer: Likelihood of Approval
IPP-204106 is under clinical development by Immupharma and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...